Vaxcell-Bio Therapeutics Co., Ltd. (KOSDAQ: 323990)
South Korea
· Delayed Price · Currency is KRW 13,940
-140 (-0.99%)
Sep 10, 2024, 9:00 AM KST
Vaxcell-Bio Therapeutics Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 |
| Net Income | -10,432 | -10,274 | -6,825 | -4,763 | -3,984 | -1,254 | Upgrade
|
| Depreciation & Amortization | 834.3 | 399.68 | 311.34 | 257.25 | 185.31 | 184.73 | Upgrade
|
| Loss (Gain) From Sale of Assets | 22.51 | - | 0.05 | 0.25 | - | 8.58 | Upgrade
|
| Loss (Gain) From Sale of Investments | -11.97 | 126.84 | - | - | - | - | Upgrade
|
| Stock-Based Compensation | 237.31 | 181.65 | 38.22 | 46.92 | 132.03 | 100.63 | Upgrade
|
| Other Operating Activities | -567.15 | 375.95 | 713.6 | 350.44 | 535.3 | -1,946 | Upgrade
|
| Change in Inventory | -158.09 | -96.74 | - | - | - | - | Upgrade
|
| Change in Other Net Operating Assets | -476.87 | -136.3 | -282.79 | -553.84 | -171.64 | -683.71 | Upgrade
|
| Operating Cash Flow | -10,555 | -9,423 | -6,045 | -4,662 | -3,303 | -3,589 | Upgrade
|
| Capital Expenditures | -1,464 | -165.8 | -167.38 | -2,124 | -26.91 | -821.9 | Upgrade
|
| Sale of Property, Plant & Equipment | - | - | - | - | - | 24.55 | Upgrade
|
| Sale (Purchase) of Intangibles | -849.62 | -32.7 | -122.83 | -104.05 | -5.02 | -80.8 | Upgrade
|
| Investment in Securities | -51,910 | -50,998 | 4,998 | -1,000 | -20,000 | 3,001 | Upgrade
|
| Other Investing Activities | -1,002 | -590.65 | -373.99 | -9 | -17.41 | -50 | Upgrade
|
| Investing Cash Flow | -55,226 | -51,787 | 4,333 | -3,237 | -20,049 | 2,073 | Upgrade
|
| Long-Term Debt Repaid | - | -216.66 | -207.85 | -205.83 | -185.75 | -154.98 | Upgrade
|
| Net Debt Issued (Repaid) | -491.81 | -216.66 | -207.85 | -205.83 | -185.75 | -154.98 | Upgrade
|
| Issuance of Common Stock | 71,790 | 71,790 | - | 597.38 | 29,366 | 1,300 | Upgrade
|
| Repurchase of Common Stock | -532.7 | -532.7 | - | - | - | - | Upgrade
|
| Other Financing Activities | -1,174 | -1,174 | - | -86.8 | - | - | Upgrade
|
| Financing Cash Flow | 69,591 | 69,866 | -207.85 | 304.75 | 29,180 | 1,145 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | - | - | - | - | 0 | 0 | Upgrade
|
| Net Cash Flow | 3,810 | 8,657 | -1,919 | -7,594 | 5,828 | -372.04 | Upgrade
|
| Free Cash Flow | -12,019 | -9,589 | -6,212 | -6,785 | -3,330 | -4,411 | Upgrade
|
| Free Cash Flow Margin | -17269.10% | -69872.25% | - | - | - | - | Upgrade
|
| Free Cash Flow Per Share | -511.65 | -488.84 | -325.84 | -448.78 | -488.96 | -1006.28 | Upgrade
|
| Cash Income Tax Paid | 13.68 | 52.84 | 59.86 | 5.16 | -8.26 | 8.58 | Upgrade
|
| Levered Free Cash Flow | -10,230 | -7,065 | -4,650 | -6,434 | -2,291 | -15,205 | Upgrade
|
| Unlevered Free Cash Flow | -10,156 | -7,037 | -4,640 | -6,417 | -2,270 | -14,756 | Upgrade
|
| Change in Net Working Capital | 514.24 | 228.11 | -433.62 | 803.58 | -104.3 | 11,632 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.